Previous Close | 1.2300 |
Open | 1.3000 |
Bid | 1.2100 x 1400 |
Ask | 1.3000 x 2200 |
Day's Range | 1.1920 - 1.3500 |
52 Week Range | 1.0000 - 4.9300 |
Volume | |
Avg. Volume | 2,355,300 |
Market Cap | 232.951M |
Beta (5Y Monthly) | 0.88 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.4110 |
Earnings Date | Aug 01, 2022 - Aug 05, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 5.83 |
Subscribe to Yahoo Finance Plus to view Fair Value for VSTM
BOSTON, May 18, 2022--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that it has received the first "Therapeutic Accelerator Award" from the Pancreatic Cancer Network (PanCAN). The Award will support a Phase 1b/2 clinical trial of the Company’s lead investigational candidates, RAF/MEK Clamp, VS-6766, with FAK inhibitor, defactinib, to evaluate whether a more complete blockade of KRAS signaling, which is
BOSTON, May 09, 2022--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today reported financial results for the three months ended March 31, 2022 and highlighted recent progress.
Precision BioSciences (DTIL) delivered earnings and revenue surprises of 20.69% and 33.66%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?